HPLC Method for Analysis of Insulin Glargine on Chromni Column

HPLC Method for Insulin Glargine on Chromni by SIELC Technologies

High Performance Liquid Chromatography (HPLC) Method for Analysis of Insulin Glargine

Insulin Glargine is a modified form of medical insulin with the molecular formula C267H404N72O78S6. It is used in management of type 1 and type 2 diabetes. Insulin glargine differs from human insulin by replacing asparagine with glycine in position 21 of the A-chain. The patent within the European Union and the United States in 2014.

Insulin Glargine is analyzed using a Chromni stationary phase column under gradient conditions with a mobile phase composed of acetonitrile (MeCN) and water. Detection is performed by UV absorbance detection.

ColumnChromni, 4.6 x 150 mm, 3 µm, 100 A, surface coated
Mobile PhaseMeCN/H2O- 80/20 – 60/40%, 10 min
BufferH2SO4 – 0.2%
Flow Rate1.0 mL/min
DetectionUV 200 nm, UV 280 nm
Limit of Detection*200 nm – 54.8 ppb, 280 nm – 770.6 ppb
*LOD was determined for this combination of instrument, method, and analyte, and it can vary from one laboratory to another even when the same general type of analysis is being performed.

Class of Compounds
Medication
Analyzing CompoundsInsulin Glargine

Application Column

Chromni

Column Diameter: 4.6 mm
Column Length: 150 mm
Particle Size: 3 µm
Pore Size: 100 A
Column options: surface coated

Add to cart
Application Analytes:
Insulin Glargine
Application Detection:
UV Detection
SIELC Technologies usually develops more than one method for each compound. Therefore, this particular method may not be the best available method from our portfolio for your specific application. Before you decide to implement this method in your research, please send us an email to research@sielc.com so we can ensure you get optimal results for your compound/s of interest.